{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:32:26Z","timestamp":1791340346008,"version":"4.3.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1186\/ar3147","type":"journal-article","created":{"date-parts":[[2010,10,29]],"date-time":"2010-10-29T02:14:26Z","timestamp":1288318466000},"source":"Crossref","is-referenced-by-count":94,"title":["The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review"],"prefix":"10.1186","volume":"12","author":[{"given":"Charlotte Louise Maria","family":"Krieckaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geertje Margret","family":"Bartelds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Frederik","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit Jan","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"9702_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"AN Emi","year":"2010","unstructured":"Emi AN, de Carvalho JF, Artur Almeida SC, Bonfa E: Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol. 2010, 38: 82-89. 10.1007\/s12016-009-8140-3.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9702_CR2","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1002\/art.22214","volume":"54","author":"K Bendtzen","year":"2006","unstructured":"Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006, 54: 3782-3789. 10.1002\/art.22214.","journal-title":"Arthritis Rheum"},{"key":"9702_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"key":"9702_CR4","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1552-1563. 10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.","journal-title":"Arthritis Rheum"},{"key":"9702_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K: Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009, 68: 1739-1745. 10.1136\/ard.2008.092833.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B: Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 711-715. 10.1002\/art.21671.","journal-title":"Arthritis Rheum"},{"key":"9702_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 921-926. 10.1136\/ard.2006.065615.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","volume":"18","author":"N Miyasaka","year":"2008","unstructured":"Miyasaka N: Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008, 18: 252-262. 10.1007\/s10165-008-0045-0.","journal-title":"Mod Rheumatol"},{"key":"9702_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB van de Putte","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004, 63: 508-516. 10.1136\/ard.2003.013052.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003, 348: 601-608. 10.1056\/NEJMoa020888.","journal-title":"N Engl J Med"},{"key":"9702_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002, 359: 1541-1549. 10.1016\/S0140-6736(02)08512-4.","journal-title":"Lancet"},{"key":"9702_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004, 350: 876-885. 10.1056\/NEJMoa030815.","journal-title":"N Engl J Med"},{"key":"9702_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007, 56: 1226-1231. 10.1136\/gut.2006.099978.","journal-title":"Gut"},{"key":"9702_CR14","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","volume":"137","author":"K Karmiris","year":"2009","unstructured":"Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P: Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009, 137: 1628-1640. 10.1053\/j.gastro.2009.07.062.","journal-title":"Gastroenterology"},{"key":"9702_CR15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007, 56: 1232-1239. 10.1136\/gut.2006.106781.","journal-title":"Gut"},{"key":"9702_CR16","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","volume":"28","author":"RL West","year":"2008","unstructured":"West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ: Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008, 28: 1122-1126. 10.1111\/j.1365-2036.2008.03828.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"9702_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006, 130: 323-333. 10.1053\/j.gastro.2005.11.030.","journal-title":"Gastroenterology"},{"key":"9702_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A: Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008, 359: 810-820. 10.1056\/NEJMoa0706290.","journal-title":"N Engl J Med"},{"key":"9702_CR19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK de Vries","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE: Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007, 66: 1252-1254. 10.1136\/ard.2007.072397.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK de Vries","year":"2009","unstructured":"de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ: Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009, 68: 1787-1788. 10.1136\/ard.2009.109702.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR21","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/ard.2009.108787","volume":"69","author":"AW van Kuijk","year":"2010","unstructured":"van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP: Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010, 69: 624-625. 10.1136\/ard.2009.108787.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","volume":"146","author":"LL Lecluse","year":"2010","unstructured":"Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB, Bos JD, Wolbink GJ: Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010, 146: 127-132. 10.1001\/archdermatol.2009.347.","journal-title":"Arch Dermatol"},{"key":"9702_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.2006.057406","volume":"66","author":"CJ van der Laken","year":"2007","unstructured":"van der Laken CJ, Voskuyl AE, Roos JC, Stigter vW, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA: Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007, 66: 253-256. 10.1136\/ard.2006.057406.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","volume":"65","author":"A Vultaggio","year":"2010","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E: Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010, 65: 657-661. 10.1111\/j.1398-9995.2009.02280.x.","journal-title":"Allergy"},{"key":"9702_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010, 362: 1383-1395. 10.1056\/NEJMoa0904492.","journal-title":"N Engl J Med"},{"key":"9702_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/ard.2006.051540","volume":"65","author":"MS Heiberg","year":"2006","unstructured":"Heiberg MS, Rodevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, Kvien TK: Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis. 2006, 65: 1379-1383. 10.1136\/ard.2006.051540.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR27","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00296-009-0973-9","volume":"29","author":"L Goh","year":"2009","unstructured":"Goh L, Samanta A: A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int. 2009, 29: 1123-1135. 10.1007\/s00296-009-0973-9.","journal-title":"Rheumatol Int"},{"key":"9702_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ: Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009, 30: 210-226. 10.1111\/j.1365-2036.2009.04027.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"9702_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.2006.066761","volume":"66","author":"GR Burmester","year":"2007","unstructured":"Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007, 66: 732-739. 10.1136\/ard.2006.066761.","journal-title":"Ann Rheum Dis"},{"key":"9702_CR30","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1073\/pnas.86.11.4220","volume":"86","author":"AF LoBuglio","year":"1989","unstructured":"LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse\/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA. 1989, 86: 4220-4224. 10.1073\/pnas.86.11.4220.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/ar3147\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T03:04:53Z","timestamp":1581131093000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["9702"],"URL":"https:\/\/doi.org\/10.1186\/ar3147","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]},"article-number":"217"}}